Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

In this mini-review, recent insights suggest a possible role of type-2-related immunity in diseases like alopecia areata, vitiligo, and localized scleroderma, though whether this immune response benefits or worsens these conditions remains unclear.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

This study found that in mice, hyper-activated JAK-STAT1 signaling due to EGFR inhibitor treatment leads to scarring alopecia, but JAK1/2 inhibition can restore hair follicle immune privilege and promote new hair growth.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

This study suggests that particulate matter can induce inflammation in human outer root sheath cells, potentially affecting hair growth, through oxidative stress-dependent MAPK and JAK-STAT signaling pathways.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

This abstract discusses the 2021 virtual Dermatology Nurses' Association Convention, outlining key dermatological insights shared, but it presents no new research findings or clinical results.

This review synthesizes cases of biopsy-confirmed alopecia areata occurring in patients using IL-17 or IL-23 inhibitors, suggesting the need for increased awareness and further investigation into this rare adverse event.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This meeting synopsis on the 66th Annual Montagna Symposium reports no new results but outlines discussions on precision dermatology, integrating molecular insights with clinical applications for personalized skin care.

This study explored COVID-related chilblains using transcriptomics and found they showed a distinct interferon and JAK/STAT pathway activation, absent in vaccine-related chilblains, with inflammatory cell types varying over time.

Blocking the JAK/STAT pathway may help reduce skin sensitivity in Xeroderma pigmentosum.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This article discusses the autoimmune causes of alopecia areata and reports no new clinical results.

This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.

This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

In this study, researchers presented cases of cellular neurothekeoma in three male family members with early-onset in infancy, suggesting a potential genetic component and inheritance pattern, which deviates from the typical presentation seen mostly in women between 20–30 years.

In this retrospective cohort study, researchers found that exposure to 5-alpha reductase inhibitors and spironolactone in female alopecia patients was not linked to an increased risk of developing malignant or benign gynecologic tumors when compared to minoxidil use.

In this study, Wang et al. (2022) found that in patients with cutaneous lupus erythematosus, chronic lesions contained more senescent progenitor cells, marked by p16 and p21, than subacute lesions, suggesting a link between disease chronicity and cellular senescence.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This article presents a planned trial comparing radiotherapy and imiquimod for lentigo maligna treatment, noting a lack of direct evidence supporting current therapies, and aims to inform future treatment guidelines.

This quiz presents educational questions about alopecia areata, including its diagnosis and underlying mechanisms, but reports no new clinical outcomes.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.

This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.